Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q08J23

UPID:
NSUN2_HUMAN

ALTERNATIVE NAMES:
Myc-induced SUN domain-containing protein; NOL1/NOP2/Sun domain family member 2; Substrate of AIM1/Aurora kinase B; mRNA cytosine C(5)-methyltransferase; tRNA cytosine C(5)-methyltransferase; tRNA methyltransferase 4 homolog

ALTERNATIVE UPACC:
Q08J23; A8K529; B2RNR4; B3KP09; B4DQW2; G3V1R4; Q9BVN4; Q9H858; Q9NXD9

BACKGROUND:
The protein RNA cytosine C(5)-methyltransferase NSUN2 is integral to RNA methylation, impacting various cellular processes through its action on tRNAs, mRNAs, and non-coding RNAs. By promoting cytosine C(5)-methylation, NSUN2 stabilizes these RNAs, facilitating key biological functions such as protein synthesis, cell differentiation, and mRNA export. Its activity is also linked to the processing of non-coding RNAs into regulatory small RNAs, playing a role in cellular growth and proliferation.

THERAPEUTIC SIGNIFICANCE:
Given the critical role of NSUN2 in Intellectual developmental disorder, autosomal recessive 5, targeting this protein could offer new avenues for treatment. The exploration of RNA cytosine C(5)-methyltransferase NSUN2's function presents a promising frontier for developing innovative therapeutic approaches to combat RNA methylation-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.